| Literature DB >> 31127184 |
Qinghua Yang1, Yang Liu1, Yewen Guan1, Xinli Zhan1, Zengming Xiao1, Hua Jiang2, Qingjun Wei3.
Abstract
The purpose of this study was to investigate the association of Vitamin D Receptor (VDR) gene polymorphisms and VDR levels with lumbar disc degeneration (LDD). TaqMan SNP Genotyping Assay was utilized to probe VDR gene polymorphisms including the FokI (rs2228570), ApaI (rs7975232) and TaqI (rs731236) in 454 patients with LDD and 485 controls. Enzyme-Linked Immunosorbent Assay (ELISA) was used to detect plasma VDR levels. The patients with LDD were divided into three subgroups (subgroup 1: lumbar disc herniation; subgroup 2: lumbar spinal stenosis; subgroup 3: lumbar spondylolisthesis) to further probe the association of plasma VDR levels and VDR gene polymorphisms and LDD. Moreover, immunohistochemistry (IHC) was implemented to evaluate VDR expression in lumbar degenerated disc and normal disc. Allele and genotype frequency of TaqI (rs731236) were significantly different in patients with LDD and controls (all P < 0.05). For TaqI polymorphism, the frequencies of T allele were significantly higher in the LDD patients compared with controls (OR = 1.319; 95%CI 1.091 to 1.595; P = 0.004, adjusted (OR = 1.319; 95%CI 1.091 to 1.595; P = 0.004, adjusted OR = 1.383; 95%CI 1.135 to 1.684; P = 0.016). Furthermore, the allele distribution showed a higher frequency of the T allele in the patients with lumbar disc herniation in subgroup 1 (OR = 1.384; 95% CI 1.105 to 1.732; P = 0.004, adjusted OR = 1.319; 95%CI 1.091 to 1.595; P = 0.016). Plasma VDR levels and VDR expression were significantly lower in patients with LDD compared with controls (all P < 0.05). Moreover, the TT genotype of TaqI polymorphism was significantly associated with lower plasma VDR levels in patients with LDD (P = 0.002). TaqI (rs731236) polymorphism was associated with a predisposition to LDD. Plasma VDR and VDR expression levels may be the marker for the occurrence and development of LDD.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31127184 PMCID: PMC6534588 DOI: 10.1038/s41598-019-44373-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of the study subjects between control and case groups including three subgroups.
| Characteristics | Control group | Case group# | Subgroup 1 | Subgroup 2 | Subgroup 3 | |
|---|---|---|---|---|---|---|
| Age (years) | (median, years) | 54.2 (15.6–62.4) | 51.6 (16.8–84.4) | 42.2 (16.8–76.4)* | 61.8 (24.3–84.4) | 57.3 (24.3–77.5) |
| Gender | Males, n (%) | 252 (52.1) | 259 (57.0) | 184 (71.0) | 54 (20.8) | 21 (8.1) |
| Females, n (%) | 233 (47.9) | 195 (43.0) | 81 (41.5) | 52 (26.7) | 62 (31.8) | |
| BMI in kg/m2 | Mean ± SD | 24.15 ± 2.93 | 24.01 ± 6.37 | 23.44 ± 3.45 | 24.10 ± 3.23 | 24.31 ± 3.53 |
| Past or current smokers | n (%) | 175 (36.1) | 169 (37.2) | 120 (45.3) | 35 (33.0) | 14 (16.9) |
#Case group composed of the Subgroup 1, Subgroup 2, and Subgroup 3. *Compared with control group, P value is less than 0.05.
Age is the actual age when participants were included in this study.
Allele and genotype distributions of ForkI (rs2228570), ApaI (rs7975232) and TaqI (rs731236) in control and case groups or subgroups.
| Polymorphisms | Genotype (%) | Allele (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AA (ff) | AG (Ff) | GG (FF) | P(χ2) | P* | A (f) | G (F) | P(χ2) | P* | OR (95% CI) | Adjusted OR#(95% CI) | HWE | |
| Controls (n = 485) | 126 (26.0) | 225 (46.4) | 134 (27.6) | 477 (49.2) | 493 (50.8) | 0.113 | ||||||
| Cases (n = 454) | 122 (26.9) | 207 (45.6) | 125 (27.5) | 0.949 | 0.999 | 451 (49.7) | 457 (50.3) | 0.830 | 0.999 | 0.980 (0.818–1.175) | 1.021 (0.851–1.222) | 0.061 |
| Subgroup1 (n = 266) | 76 (28.6) | 123 (46.2) | 67 (25.2) | 0.666 | 0.999 | 275 (51.7) | 257 (48.3) | 0.351 | 0.999 | 0.904 (0.732–1.117) | 1.108 (0.894–1.374) | 0.227 |
| Subgroup2 (n = 105) | 26 (24.8) | 48 (45.7) | 31 (28.5) | 0.918 | 0.999 | 100 (47.6) | 110 (52.4) | 0.683 | 0.999 | 1.064 (0.790–1.435) | 0.914 (0.687–1.277) | 0.683 |
| Subgroup3 (n = 83) | 20 (24.1) | 36 (43.4) | 27 (32.5) | 0.657 | 0.999 | 76 (45.8) | 90 (54.2) | 0.419 | 0.999 | 1.146 (0.824–1.594) | 0.990 (0.626–1.222) | 0.250 |
| AA (aa) | AC (Aa) | CC (AA) | P ( | P* | A (a) | C (A) | P ( | P* | OR (95% CI) | Adjusted OR# (95% CI) | HWE | |
| Controls (n = 485) | 50 (10.3) | 191 (39.4) | 244 (50.3) | 291 (30.0) | 679 (70.0) | 0.170 | ||||||
| Cases (n = 454) | 34 (7.5) | 203 (44.7) | 217 (47.8) | 0.137 | 0.548 | 273 (30.1) | 635 (69.9) | 0.942 | 0.999 | 1.007 (0.827–1.228) | 1.001 (0.814–1.209) | 0.149 |
| Subgroup1 (n = 266) | 20 (7.5) | 116 (43.6) | 130 (48.9) | 0.323 | 0.999 | 156(29.3) | 376 (70.7) | 0.784 | 0.999 | 1.033 (0.819–1.301) | 1.024 (0.750–1.201) | 0.395 |
| Subgroup2 (n = 105) | 7 (6.7) | 50 (47.6) | 48 (45.7) | 0.225 | 0.900 | 64 (30.5) | 146 (69.5) | 0.891 | 0.999 | 0.978 (0.707–1.352) | 0.940 (0.745–1.462) | 0.205 |
| Subgroup3 (n = 83) | 7 (8.4) | 37 (44.6) | 39 (47.0) | 0.643 | 0.999 | 51(30.7) | 115 (69.3) | 0.851 | 0.999 | 0.966 (0.676–1.381) | 0.978 (0.744–1.534) | 0.667 |
| AA (tt) | AG (Tt) | GG (TT) | P ( | P* | A (t) | G (T) | P ( | P* | OR (95% CI) | Adjusted OR# (95% CI) | HWE | |
| Controls (n = 485) | 63 (13.0) | 246 (50.7) | 176(36.3) | 372 (38.1) | 598 (61.9) | 0.109 | ||||||
| Cases (n = 454) | 32 (7.0) | 227(50.0) | 195 (43.0) | 0.004 | 0.016 | 291 (32.0) | 617 (68.0) | 0.004 | 0.016 | 1.319 (1.091–1.595) | 1.383 (1.135–1.684) | 0.001 |
| Subgroup1 (n = 266) | 17 (6.4) | 131 (49.2) | 118 (44.4) | 0.007 | 0.028 | 165 (31.0) | 367 (69.0) | 0.004 | 0.016 | 1.384 (1.105–1.732) | 1.420 (1.151–1.842) | 0.013 |
| Subgroup2 (n = 105) | 8 (7.6) | 54 (51.4) | 43 (41.0) | 0.275 | 0.999 | 70 (33.3) | 140 (66.7) | 0.173 | 0.692 | 1.244 (0.908–1.704) | 1.202 (0.878–1.611) | 0.107 |
| Subgroup3 (n = 83) | 7 (8.4) | 42 (50.6) | 34 (41.0) | 0.446 | 0.999 | 56 (33.7) | 110 (66.3) | 0.257 | 0.999 | 1.222 (0.864–1.729) | 1.215 (0.872–1.756) | 0.230 |
OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium; P*, Bonferroni-corrected P value; Adjusted OR#(95% CI), OR adjusted for age.
Figure 1Plasma VDR levels in control (n = 485) and case (n = 454) groups, including subgroup 1 (n = 266), subgroup 2 (n = 105) and subgroup 3 (n = 83). (A) Plasma VDR levels was significant higher in the control group than those in the case group (P < 0.01). (B) Plasma VDR levels was significant higher in the control group than those in the subgroup 1, 2, and 3 respectively. Data represent the median, the unit is ng/L. The yellow line indicates a statistically significant difference (P < 0.05) and the black line indicates no statistically significant difference (P > 0.05). (C) Plasma VDR levels was significant higher in patients with rs731236 tt/Tt genotypes (n = 259) than those in the patients with TT genotype (n = 195). The line in the box represents the median. The interval of box is the 25th and 75th percentiles. The interval of whiskers is the 5th and 95th percentiles.
Figure 2VDR expression was analyzed by immunohistochemistry assay. Expression of VDR was higher in the control group (A,B) than that in the case group (C,D). (Magnification, 400×) Black arrowheads show VDR positive cells.
Figure 3Classification of patients into subgroups by MRI imaging. (A) Subgroup 1: patients with lumbar disc herniation; white arrow indicates L4/5 herniated disk bulges out toward the spinal canal. (B) Subgroup 2: patients with lumbar spinal stenosis; white arrows indicate L3-4 level spinal stenosis caused by degenerative thickening of the ligamentum flavum. (C) Subgroup 3: patients with lumbar spondylolisthesis; white arrow indicates subluxation of L5 vertebral body relative to S1 vertebral body.